Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SILO PharmaSILO 42 EV-to-EBITDA is 0.40 as of Sep. 11, 2026. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 403 Biotechnology companies, SILO Pharma ranks better than 87.84% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SILO Pharma's enterprise value is $-1.75 Mil.
SILO Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-4.42 Mil. Therefore, SILO Pharma's EV-to-EBITDA for today is 0.40.
The historical rank and industry rank for SILO Pharma's EV-to-EBITDA or its related term are showing as below:
SILO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -370.86 Med: -0.42 Max: 3.37
Current: 0.4
During the past 13 years, the highest EV-to-EBITDA of SILO Pharma was 3.37. The lowest was -370.86. And the median was -0.42.
SILO's EV-to-EBITDA is ranked better than 87.84% of 403
companies
in the Biotechnology industry
Industry Median: 13.21
vs SILO: 0.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SILO Pharma's PE Ratio (TTM) for today is calculated as:
SILO Pharma's share price for today is $2.10.
SILO Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.353.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for SILO Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SILO Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SILO Pharma's EV-to-EBITDA falls into.
SILO Pharma's current Enterprise Value is $-1.75 Mil.
SILO Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (SILO) has a EV-to-EBITDA of 0.40 as of Sep. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SILO Pharma. According to the industry distribution chart, SILO Pharma ranks #49 out of 403 companies in the Biotechnology industry, placing it in the top 12.2%.
Is SILO Pharma's EV-to-EBITDA too high?
SILO Pharma's current EV-to-EBITDA is 0.40. The Biotechnology industry median EV-to-EBITDA is 13.21. SILO Pharma's value of 0.40 is 97% below this industry median. Based on the distribution chart, SILO Pharma ranks #49 out of 403 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's EV-to-EBITDA compare to ELAB and GLMD?
According to the Biotechnology industry distribution chart, SILO Pharma ranks #49 out of 403 companies for EV-to-EBITDA. This places SILO Pharma in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.21. SILO Pharma's value of 0.40 is 97% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.21, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SILO Pharma's current EV-to-EBITDA of 0.40 is 97% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SILO Pharma. For the Biotechnology industry, the median EV-to-EBITDA is 13.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SILO Pharma's current EV-to-EBITDA is 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current EV-to-EBITDA is 0.40 and 97% below the Biotechnology industry median of 13.21. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SILO Pharma (SILO), the current EV-to-EBITDA is 0.40 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SILO Pharma (SILO) Overvalued in 2026?
Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued.
The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44.
GuruFocus considers SILO Pharma to be Possible Value Trap.
Key valuation signals for SILO:
EV-to-EBITDA: 0.40
GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
Industry Position: 97% below the Biotechnology median (#49 of 403)
No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score
Get the complete analysis for SILO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SILO has been successfully added to your 
